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The NADPH oxidase is an electron transport chain in ‘‘professional’’ phagocytic cells that transfers electrons from NADPH in the
cytoplasm, across the wall of the phagocytic vacuole, to form superoxide. The electron transporting flavocytochrome b is activated by the
integrated function of four cytoplasmic proteins. The antimicrobial function of this system involves pumping K+ into the vacuole through
BKCa channels, the effect of which is to elevate the vacuolar pH and activate neutral proteases. A number of homologous systems have been
discovered in plants and lower animals as well as in man. Their function remains to be established.
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1. Introduction NADPH oxidase (NOX) systems transport electrons across
membranes—in addition to their essential role in innateThe NADPH oxidase is found in ‘‘professional’’ phag-
ocytes including neutrophils (PMN), eosinophils, mono-
cytes and macrophages, cells that form the core of the
innate immune system, and is required for their efficient
function. These cells circulate in the blood and migrate
through capillaries into the tissues where they crawl be-
tween cells in search of bacteria, fungi and tissue debris,
which they engulf and digest (Fig. 1).
This multi-component enzyme complex is of particular
interest because it is the prototype of a newly discovered
family of electron transport systems that consist of a
transmembrane flavocytochrome that interacts with a variety
of activating cytosolic proteins, including a small GTP-
binding protein. The discovery of this system and the
elucidation of its components, organization and regulation
have been important in its own right for developing our
understanding of innate immune mechanisms. In the last
few years the identification of a number of homologous
electron transport chains in a variety of tissues in mammals,
and in plants, has greatly increased the general involvement
of such systems in biology in its widest sense. These0005-2728/$ - see front matter D 2004 Published by Elsevier B.V.
doi:10.1016/j.bbabio.2004.03.008
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E-mail address: t.segal@ucl.ac.uk (A.W. Segal).immunity, they have been shown to be important for such
diverse processes as the development of roots in plants
[104], cuticle in C. elegans [94] and wings in Drosophila.2. Respiratory burst—history
The ‘‘extra respiration of phagocytosis’’ was first de-
scribed by Baldridge and Gerrard in 1933 [16] when they
noticed that neutrophils demonstrated a dramatic increase in
oxygen uptake when phagocytosing bacteria. It was assumed
for many years that this ‘‘respiratory burst’’ was a response of
the cell’s mitochondria to provide the extra energy required to
engulf the particles. It was only when the respiratory burst
was shown to be insensitive to classic inhibitors of mito-
chondrial oxidative metabolism such as cyanide and azide
[255] that the unusual nature of this process was realised. It
was subsequently found to be essential for the efficient killing
of microbes that were adequately engulfed, but not killed, in
the absence of oxygen [274].
2.1. CGD—description
Chronic granulomatous disease (CGD) [296] is a rare
inherited disorder characterized by the absence of NADPH
1 In fact, the reduced-minus-oxidized absorbance maximum of human
flavocytochrome b558 is 559.3 nm at room temperature.
Fig. 1. Electron micrograph of neutrophil. A section through a neutrophil
(about 10 Am in diameter) containing 10 S. aureus within phagocytic
vacuoles taken after about 30 s. after mixing the cells and bacteria. Granules
can be seen in the cytoplasm and degranulating into the vacuoles in which
granule contents can also be seen.
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genes coding for its component proteins, most of which, as
well as the functions of the proteins themselves, have been
identified through the study of cells from patients with this
syndrome.
Phagocytes lacking NADPH oxidase activity are unable
to kill bacteria and fungi efficiently, with the predicted
consequence that these patients are profoundly immunode-
ficient, demonstrating frequent, severe, acute and chronic,
often fatal, infections.
Treatment consists of prophylactic and therapeutic anti-
biotics. Bone marrow transplantation can be effective and
gene therapy offers potential for the future.
2.2. Identification of the nature of the oxidase
Enormous difficulties were experienced in the identifica-
tion and purification of this oxidase, causing it to be labeled
the ‘‘elusive pimpernel’’ [15]. The earliest experiments
attempted to purify the oxidase fromwhole-cell homogenates
and crude subcellular fractions, which were incubated with a
variety of potential substrates to demonstrate oxidase or
diaphorase activity [169]. A variety of activities were de-
tected, but the interpretation of these experiments was com-
plicated by the lack of specificity of the oxidation of many of
these substrates and the autocatalytic nature of many of the
resulting reactions, accelerated by the presence of metal ions,
lipids and reductants in the reaction mixture. Although a
number of disparate ‘‘enzymes’’ were discovered and de-
scribed as defective in CGD, none stood the test of time.
Despite the development of a solubilised active oxidase
[20,110,292,306] from stimulated cells, complete purifica-tion proved impossible because of its instability, particularly
its exquisite sensitivity to salts, which prevented most
chromatographic separations [19].
2.3. The NADPH oxidase is a transmembrane electron
transport chain containing a flavocytochrome b—discovery,
rediscovery, controversy and resolution
A great deal of frustration could have been avoided had
the observation in the early 1960s of a b-type cytochrome in
neutrophils been more widely recognized. These descrip-
tions [134] were of the molecule responsible for stable
NADI oxidase activity. This reaction, which produces a
blue compound, indophenolblue, from dimethyl para-phe-
nylen diamine and a-napthol [146], was originally thought
to be produced by a specific enzyme, indophenol oxidase,
but later shown to be a nonspecific indicator of oxidases.
Subsequently it was also shown to be associated with rabbit
neutrophils, localising to the granules [278]. In a thorough
chromatographic characterisation of this cytochrome, the
possibility was even raised that this new cytochrome might
have something to do with neutrophil respiration insensitive
to cyanide and antimycin A [277]. This linkage was never
clearly made, possibly because it was thought the cyto-
chrome might be an unusual cytochrome P420 (an inacti-
vated form of cytochrome P450), and these reports in the
Japanese literature were overlooked [169,170].
The b-type cytochrome was rediscovered in human
neutrophils and shown to be missing in the commonest
(X-linked) form of CGD [268,269]. When it was initially
purified [133], only a single protein that ran on SDS gels
with a molecular mass of about 60–100 kDa (because of
its heavy glycosylation [132]) co-purified with the haem.
This protein was initially called cytochrome b558 and its
gene was found by positional cloning and shown to be
abnormal in patients with X-CGD [252,294]. Subsequently
the cytochrome was shown to be a heterodimer, when a
22-kDa protein co-purified with the haem and the larger
protein. Both subunits were shown to be missing in X-
CGD [231,257]. The larger and smaller proteins were then
called the h and a subunits, respectively, and subsequently
gp91phox and p22phox.
Initially, there was strong resistance to the idea that this
cytochrome might be part of the oxidase (thought at the
time to be a flavoprotein [117]), especially when it was
shown to be present in some CGD patients and not others
[25]. Ultimately, it has been clearly demonstrated that the
catalytic core of the NADPH oxidase is a membrane-
bound flavocytochrome, containing two molecules of haem
and one molecule of flavin adenine dinucleotide (FAD)
[60,89,102,174,272] with an absorbance maximum of the
a band near 558 nm.1 For this reason, it is now usually
referred to as flavocytochrome b558.
Fig. 2. Model of gp91phox model. The six transmembrane helices and NH2-
and COOH-terminal tails are arranged as indicated. The two non-identical
haems are located within the membrane as shown. The haem with
Em7 = 265 mV is toward the outer face of the membrane coordinated
between His115 and His222. The inner haem, Em7 = 225 mV is
coordinated by His101 and His209. Arg54, which is hydrogen bonded to
the propionate side chain of the outer haem, is indicated. The cytosolic
NADPH and FAD-binding regions are shown toward the C-terminus of the
protein. In the membrane, gp91phox is tightly associated with the p22phox
subunit (not shown).
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3.1. Structure and energetics
3.1.1. gp91phox (b-subunit, NOX2, CYBB gene)
Flavocytochrome b558 is a membrane-bound heterodi-
meric protein consisting of one molecule of p22phox (a-
subunit, the production of the CYBA gene) and one molecule
of gp91phox (h-subunit, CYBB gene) [85,86,148,257,307]
(Table 1).
Flavocytochrome b558 contains all the catalytic machin-
ery for the oxidation of cytosolic NADPH and the reduction
of O2 to form O2
. This enzymatic process requires the
participation of three redox co-factors: one molecule of FAD
and two molecules of iron protoporphyrin IX (haem b)
[51,53,219]. The haem groups are nonequivalent [219] and
have different redox potentials [60] (Section 3.1.5). All
these redox centers, as well as the NADPH binding site,
are located on gp91phox [88,240,272,293,326].
gp91phox is a heavily glycosylated (f 85–100 kDa)
N-linked glycoprotein [132] with a 65-kDa protein core
(Fig. 2).
3.1.2. gp91phox C terminus: NADPH and FAD binding
The hydrophilic C-terminal (282–570) portion of
gp91phox contains the FAD and NADPH binding sites that
have distant but recognizable homology to the large family
of ferredoxin-NADP reductase (FNR) proteins, of which
cytochrome P450 reductase, nitric oxide synthase
[272,293] and yeast ferric reductase [276] are members.
The FAD is non-covalently bound with a Kd of 20–70
nM, a value that is probably partly dependent on the lipid
environment [177,179,181,222,230,326]. Consistent with
these observations are the existence of a number of
naturally occurring CGD mutations within the FAD andTable 1
Properties of the phagocyte respiratory burst oxidase (phox) components
gp91phox p22phox p47phox
Gene and locus CYBB; Xp21.1 CYBA; 16q24 NCF-1; 7q1
Amino acids 570 195 390
Molecular weight:
Predicted 65,338 Da 20,959 Da 44,684 Da
By SDS-PAGE f 90 kDa 22 kDa 47 kDa
Glycosylation Yes No No
pI 9.26 10.1 9.58
Phosphorylation No Minor Yes
Location in PMN





















regionNADPH binding motifs that ablate binding of the appro-
priate nucleotide. As expected, these motifs are also well
conserved within the other members of the NADPH
oxidase (NOX) family (Fig. 3 and Section 10). The overall
homology of the cytosolic domain to the FNR family has
allowed modeling studies to be made that suggest the
presence of a large insertion that could potentially function
as a regulatory domain [293]. In keeping with this notion,
there is considerable evidence from the literature that there
are multiple direct interactions between both p47phox andp67phox p40 phox Rac2
1.23 NCF-2; 1q25 NCF-4; 22q13.1 Rac2; 22q13.1
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Fig. 3. Structural motifs in the NOX/DUOX family. Structural motifs in the family members are present as indicated. See text for details.
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thought to overlie the NADPH binding site (450–504)
[293] and between p47phox and the extreme N-terminal part
of gp91phox [79,191,192,251].
3.1.3. gp91phox N-terminus: haem co-ordination
The hydrophobic N-terminal half of gp91phox contains
six membrane-spanning a-helices. Helices III and V each
contain two histidine residues appropriately positioned
(101:209 and 115:222) to co-ordinate two haem prosthetic
groups perpendicular to the plane of the membrane (Fig. 2).
These histidine residues are completely conserved among all
the NOX family members. Site-directed mutagenesis studies
support the proposal that these histidine residues form
the axial ligands to the haem groups [21,102]. Resonance
Raman [149], visible, CD [322] and EPR [107,108,206,301]
spectroscopy are all consistent with low-spin (hexacoordi-
nate) configuration of both haem groups, implying that
electron transfer to oxygen occurs via the haem edge rather
than through direct coordination to the haem iron. This is in
keeping with the known insensitivity of the oxidase to
cyanide, azide and carbon monoxide, classic haem ‘‘poi-
sons’’. Interestingly, this outer-sphere process is exactly the
mechanism of the reverse reaction between O2
 and cyto-
chrome c, which is the most common method used to detect
O2
 production. Despite this well-documented fact, many
researchers argue that O2 ‘‘must’’ bind directly to the haem
iron. It has been suggested that one (or possibly both)
haem(s) may undergo a low-spin to high-spin transition
during activation of the oxidase which might allow direct
oxygen binding to the haem-iron and/or promote proton
conductance through gp91phox (Section 8.1) [90,199]. How-
ever, this would appear to be contrary to the careful studies
of Fujii et al. [107,108] and Isogai et al. [150,151], who
have presented extensive evidence that the active form of
NADPH oxidase requires the haem to be in the low-spin
(hexacoordinate) state. The predicted placing of the haem
groups (one toward the inner face and one toward the outer
face) is consistent with their function to transport electrons
from the NADPH (via FAD) on the inside (cytosol) acrossthe membrane to the interior of the phagocytic vacuole
where molecular O2 is reduced to form O2
. In biology,
transmembrane electron transport is very often (but not
exclusively) by means of di-haem membrane proteins.
Two haems are required to span the width of the membrane
to allow electrons to transfer at kinetically significant rates.
Within proteins, electron transfer rates fall off exponentially
with the distance between donor and acceptor, with a f 10-
fold decrease in rate for every 1.7-A˚ separation [225].
Biological membranes are f 25-A˚ thick and thus at least
two redox centers are required. The proposed spacing and
orientation of the haems in gp91phox is consistent with other
known cytochromes that function to transport electrons
across membranes and is very similar to that of the mito-
chondrial bc1 complex where members of the pair of
histidine axial ligands are also f 100 amino acids apart
and axial pairs 14 amino acids apart [321]. p22phox contains
an invariant histidine residue (H94) that had been proposed
as one of the axial ligands to one of the haem groups.
Recent site-directed mutagenesis studies have conclusively
shown this not to be the case [22].
The second (120–167) and third (224–257) external
loops of gp91phox contain the N-linked glycosylation sites
(asparagines 132, 149 and 240) [308]; these are only partly
conserved among mammals. During synthesis of flavocyto-
chrome b558, haem insertion into gp91
phox is required before
heterodimer formation, which in turn precedes glycosylation
[77,324]. Although the human neutrophil flavocytochrome
b558 is heavily glycosylated, this appears to vary among
phagocytes and among species [172]. Glycosylation is not a
requirement for gp91phox catalytic function [223].
3.1.4. p22phox
p22phox is a 194-amino-acid (f 21 kDa) protein with a
hydrophobic, membrane-spanning N-terminus (1–132) that
crosses the membrane at least two (and possibly four) times.
The cytoplasmic hydrophilic C-terminus (133–194) con-
tains a proline-rich domain (151–160) that is known to be
important in binding of p47phox to flavocytochrome b558
[189,288]. A naturally occurring mutation in this domain
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abolished translocation of p47phox and p67phox to the mem-
brane after neutrophil activation and resulted in CGD [193].
Other regions of p22phox have also been implicated as sites
of interaction between p22phox and both p47phox and p67phox
[67]. Thus, it seems likely that the only function of p22phox
is to provide high-affinity binding sites for the cytosolic
NADPH oxidase subunits. It is noteworthy, however, that
for full processing and maturation, association of gp91phox
and p22phox is required, at least in neutrophils [77].
In neutrophils, the stable expression of each subunit is
mutually dependent on the expression of the other. Thus,
mutations causing the loss of p22phox expression in CGD
lead to the loss of expression of both p22phox and gp91phox
subunits and vice versa. This does not apply to all cell types,
however, and low level p22phox expression can be detected in
many cell types and tissues in the absence of gp91phox
[232,233]. Similarly, in cell-lines, gp91phox has been
expressed in the absence of p22phox. By using such model
systems, it has been possible to confirm that all the redox
centers are contained within the gp91phox subunit [325].
3.1.5. Energetics of the flavocytochrome b558 redox centers
The redox potentials of the flavin redox couples have
been measured using EPR spectroscopy by Kakinuma
[160] as Em1 = 256 mV (FAD/FADS) and Em2 = 304
mV (FAD
S
/FADH2) with the formation of a neutral
semiquinone, although this semiquinone does not accu-
mulate to a significant extent during enzyme turnover
[95,179]. Thus, the overall midpoint potential of the FAD
center is  280 mV (for comparison, the Em of the
NADPH/NADP couple is f 317 mV).
The redox potentials of the haems in gp91phox are
 225 and  265 mV at pH 7.0. When first determined,
these potentials were too close together to be distinguished
[56], but the serendipitous discovery of an X-linked CGD
patient with an Arg54! Ser mutation in gp91phox allowedFig. 4. Electron transfer pathways within flavocytochrome b558. The seven electron
the cytosol, across the membrane to the phagocytic vacuole. See text for details.the dissection of redox titration curves into two separate
components. In the mutant, the haem center with
Em7 = 265 was shifted to  300 mV making deconvo-
lution of the titration possible [56,60]. Structural compar-
isons with other membrane cytochromes suggest that
invariant arginine residues near the membrane surface form
hydrogen bonds with the negatively charged propionyl side
chains of the membrane-embedded haem. Arg54 is pre-
dicted to be at the outer membrane surface in a position
where it could perform this function. Substitution of the
positively charged arginine to an uncharged serine would
decrease the electron withdrawing nature of this group and
thus lower the redox potential of the haem (in this case by
35 mV). Similar effects have been demonstrated in yeast
iso-1-cytochrome c when glutamine ( 30 mV) or aspar-
agine ( 34 mV) was substituted for the equivalent
arginine that forms a hydrogen bond with one of the haem
propionate side chains [66]. In combination, these obser-
vations allow the assignment of the redox potentials to the
individual haem groups in the wild-type enzyme; the inner
haem having Em7 = 225 mV and the outer haem Em7 =
 265 mV.
Although not formally proven, it is now generally
believed that NADPH oxidase does not contain any other
redox centers or redox-active metal ions, although p67phox
has been reported to be capable of (vanishingly) small rates
of NADPH oxidase activity at high NADPH concentrations
[69].1 Early reports suggested the involvement of ubiqui-
none [41,42,111] or pyrroloquinoline quinone (PQQ) [23] in
oxidase function, but these appear to have been artifactual
[55,196].
3.1.6. Electron transfer mechanism
There are seven separate steps of electron transfer during
a single turnover of NADPH oxidase, as illustrated in Fig. 4.
The initial step is the transfer of two electrons from NADPH
to oxidized FAD. As in many biological processes, FAD (ortransfer steps are numbered. Electron transfer takes place from NADPH in
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processes into single electron transfer steps in cases where
only one (or an odd number of) electron(s) are required for
an enzymatic reaction [309]. The stereochemistry of the
hydride transfer has been determined to be from the 4-pro R
position of NADPH, as is the case with other members of
the FNR family, by measurement of the kinetic deuterium
isotope effect [218]. The Km for NADPH has been generally
reported to be in the range 25–35 AM for neutrophil plasma
membranes and slightly lower for purified flavocytochrome
b558. The Km for NADH is at least 10–20 times higher, thus
the oxidase exhibits a marked preference for NADPH. At
the prevailing intracellular concentrations of NADH and
NADPH (both f 70 AM), it undoubtedly utilizes the latter
almost exclusively. This initial electron transfer process
appears to be the principal rate-limiting step of oxidase
turnover. Although it is frequently suggested that the oxi-
dase is regulated by changes in nucleotide-binding (i.e.
through alteration of Km NADPH), there is little experimen-
tal evidence that this is the case—consistent with labeling
studies, where NADPH analogues appear to label resting or
activated flavocytochrome b558 with approximately equal
efficiency [88,240,272].
The second electron transfer step is from reduced FAD
(FADH2, Em= 304 mV) to the inner haem (Em= 225
mV) (Fig. 5), generating the FAD semiquinone (FAD
S
). In
the third and fourth steps, the electron is passed from the
inner to the outer haem (Em = 265 mV) and thence to
oxygen forming superoxide (Em = 160 mV). The reported
Km for oxygen varies quite widely in the literature, but most
values are in the range of 5–10 AM. The fifth, sixth and
seventh steps recapitulate the third, fourth and fifth, the
exception being in the fifth step, where it is the flavin
semiquinone (Em = 256 mV) that is the donor to the inner
haem, and thus the driving force for electron transfer is less.
Two points are noteworthy: first, little flavin semiqui-
none is observed during enzyme steady-state enzyme turn-Fig. 5. The energetics of electron flow within flavocytochrome b558. Note that
(Em O2
/O2 = 160 mV) is energetically favourable, transfer from the inner ha
from FAD to haem during the reaction cycle (steps 2 and 5 in Fig. 3) areover, despite there being measurable amounts of reduced
FAD [95,181]. This is consistent with the reactions involv-
ing haem being more rapid than the reactions involving
FAD. The degree of flavin reduction reported in the litera-
ture is also quite variable ( < 5–40%) probably due to
differences in enzyme preparation, intrinsic enzyme activity
and reaction conditions (amphiphile and cytosolic factors)
that in turn determine the degree to which flavin reduction is
the rate-limiting step [46,51,59,177,179,218]. Second, the
third and sixth steps in this electron transfer scheme are
energetically unfavorable, since the inner haem has a higher
midpoint redox potential than the outer haem (Fig. 5). It is
not known if this unexpected arrangement has a functional
significance, but it may partially explain that the presence of
oxygen is necessary for rapid electron flow of electrons into
and through NADPH oxidase, as the absence of a terminal
electron acceptor will cause electrons to accumulate on the
inner haem. Under anaerobic conditions, the rates of flavin
and haem reduction are approximately 1000 times slower
than the known rate of electron transfer in the aerobic
enzyme [51,177]. The slow rate of anaerobic haem reduc-
tion has been used as an argument to ‘‘prove’’ that haem of
gp91phox is not involved in catalysis of O2
, and that
NADPH oxidase is a simple flavoprotein (for example
[12]). This argument conveniently ignores the equally slow
kinetics of anaerobic flavin reduction! [43,53]. It has never
been clear how a flavoprotein with an internal flavin domain
(and no other active redox centers) could transfer electrons
from the cytosolic face to the outer face of the membrane.
Measurement of reoxidation rates of the reduced compo-
nents, combined with steady-state experiments, confirmed
that under aerobic conditions both haem and flavin within
NADPH oxidase are kinetically competent to generate O2

at the observed rate [59,95]. Thus, oxygen is necessary for
rapid electron flow. The ability of the haem to rapidly react
with oxygen, the appropriate steady-state levels of reduction
of haem and flavin and the ability of oxygen to acceleratethe overall electron transfer from NADPH (Em= 317 mV) to oxygen
em to the outer haem is not. In addition, the two electron transfer steps
not equivalent.
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[150,177,179,218,222]. Under optimal in vitro conditions,
flavocytochrome b558 exhibits a turnover number of around
300/s at 22 jC, with a pseudo first-order haem reoxidation
rate of 4.7 ms [48,56,59].2 p67phox and p47phox have apparent MWs of 67 and 47 kDa by SDS
gel electrophoresis.4. Cytosolic phox proteins—discovery, structures and
interactions
4.1. Discovery
The demonstration that flavocytochrome was absent in
only some CGD patients led to the identification of other
forms of the disease [25] that were inherited in an autosomal
recessive manner as a result of abnormalities in cytosolic
proteins that are also components of the system.
Most patients with autosomal pattern of inheritance of
CGD usually possess a normal flavocytochrome b558 [260].
However, their cells were unable to transfer electrons to this
molecule when stimulated [266], indicating a problem with
the activation system or a missing proximal electron trans-
porting molecule. The heterogeneity of this condition was
confirmed by complementation conferred by fusion of cells
from the subjects with the different patterns of inheritance
[128]. A 44–47-kDa protein that was normally heavily
phosphorylated upon activation of normal neutrophils was
shown to be missing in most (but not all) cases of autosomal
recessive CGD [264].
Two technical developments then led to the discovery
and characterisation of the components of the oxidase other
than flavocytochrome b558. These were as follows.
4.1.1. The development of a ‘‘cell-free’’ assay
Several groups independently developed methods of
activating the NADPH oxidase by mixing neutrophil sub-
cellular fractions with NADPH and anionic amphiphiles
(30–100 AM arachidonic acid or SDS, although other
amphipathic lipids can also fulfill this requirement)
[31,32,62,139,202]. A mixture of crude membrane prepara-
tions and factors within the cytoplasm was required for
activity. The factors missing in the cells from the majority of
autosomal recessive CGD patients were in the cytosol and
not the membrane fraction that housed the flavocytochrome
b558 [63,64], and two of these cytosolic factors appeared to
be involved [65,237].
4.1.2. The production of antibodies to p47phox and p67phox
The involvement of a GTP binding protein in the NADPH
oxidase was first suggested byGabig et al. [109] and Seifert et
al. [273] when they showed that guanine nucleotides stimu-
lated the oxidase in a cell-free system. Doussie`re et al. [91]
then demonstrated that GTP promoted the formation of a
complex between a cytosolic factor and a membrane protein.
In an attempt to purify this cytosolic protein, cytosol was
passed over a column of immobilised GTP, and the eluate,which enhanced activity in the cell-free assay, was used to
immunise rabbits. This experiment had a remarkably suc-
cessful outcome. Of all the proteins in this complex mixture,
good antibodies were only produced to two proteins, both
from the phox system, and each was missing from a
different type of autosomal recessive CGD [304]. Neither
of these two proteins was subsequently found to bind GTP.
One protein was identified as the 47-kDa phosphopro-
tein previously shown to be missing in most cases of
autosomal recessive CGD [264], and the other had a
molecular mass of about 67 kDa. The antiserum was then
used to clone the genes, coding for p47phox [305] and
p67phox [190], respectively.
4.1.3. p21rac
After the discovery of p47phox and p67phox [304], it
became clear that they were not sufficient to reconstitute
the active oxidase when combined with membranes in the
cell-free assay [237]. A GTP-dependent complementing
factor that restored oxidase activity when mixed with
p47phox, p67phox and membranes [1] was purified from
cytosol and was shown to be rac1 [2] or rac2 [173].
Although rac2 is the predominant form in neutrophils,
rac1 can compensate for its deficiency as shown by normal
oxidase activity in rac2 deficient cells [126]. Under resting
conditions, rac is coupled to another protein, GDP dissoci-
ation inhibitor (GDI), which maintains it in the inactive
form bound to GDP [236]. The lipid modification on the
tail of the rac is housed in a hydrophobic pocket in GDI
[163].
4.2. Details of cytosolic phox proteins
4.2.1. p67phox (NOXA2)
p67phox is a 59,735-Da protein2 (526 amino acids) with a
pI of 6.12. Like the other cytosolic phox proteins, p67phox is
rich in motifs involved in protein/protein interactions (Fig.
6). These include two SH3 domains (central and C-termi-
nal), two proline-rich regions flanking the central SH3
domain, an N-terminal TPR (tetratricopeptide repeat) and
a PB1 domain C-terminal to the central SH3 domain. The
TPR domains are thought to bind rac [84]. PB1 domains are
known to interact with octicosapeptide motifs [152] and
p67phox binds to p40phox through this domain [211]. As will
be described later, this protein is absolutely required to
induce electron transport through the flavocytochrome,
consequently these proteins have been called the NOXA
(NOX Activator) family. Thus, a homolog of p67phox has just
been described [17,116] and termed NOXA1. NOXA1
differs from p67phox in lacking the first SH3 domain and
possessing an additional hydrophobic region. It appears to
be co-expressed with NOX1 and NOXO1 (below) in the
colon epithelium.
Fig. 6. Regions of p40phox, p47phox and p67phox involved in protein/protein interactions. Serine residues of p47phox that are phosphorylated during oxidase
activation are indicated with arrows. See text for details of the structural motifs.
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p47phox is a basic protein (pI = 9.6) of molecular weight
44,681 Da (390 amino acids) that is heavily phosphorylated
during neutrophil activation. p47phox contains a number of
well-defined motifs (Fig. 6), including a PX domain (in-
volved in phosphoinositide binding), two SH3 domains
(involved in protein/protein interactions) and at least one
proline-rich motif (the reciprocal target for SH3 domain
interactions). This protein appears to stabilize and organize
the oxidase complex and consequently they are called the
NOXO (NOX Organizer) proteins. Consequently, the novel
homolog of p47phox that has been described very recently
[17,116] is termed NOXO1. It differs from p47phox in
lacking the auto-inhibitory domain and the pKC phosphor-
ylation sites. NOXO1 is co-expressed with NOX1 in the
colon epithelium where it appears to be involved in the
regulation of NOX1 activity.
4.2.3. p40phox
p40phox was discovered when it co-purified with p67phox
(to which it is tightly bound) [284,314]. It is a protein of
39,039 Da (339 amino acids), strongly homologous with
p47phox with an N-terminal PX domain, followed by an
SH3 domain. Towards the C-terminus, there is an octico-
sapeptide repeat (OPR [239], also known as PC domain
[211]) (Fig. 6). This domain seems to be involved in the
binding of p40phox to p67phox. This protein probably
functions as a shuttle partner, transporting p67phox, which
does not contain a PX domain, to the membrane of the
phagocytic vacuole by binding to phosphatidylinositides
(Section 7.1).5. Molecular genetics of CGD—role of the different
oxidase components
Defects in any one of four genes give rise to the known
forms of CGD [58,142,248]. CYBB (coding for gp91phox,
NOX2) is located on the X chromosome and accounts for
about 65% of cases, exclusively in males (except in rarefemale carriers where there is extreme lyonization). The
other three genes are all autosomal with NCF1 (p47phox or
NOXO2 protein) NCF2 (p67phox or NOXA2) and CYBA
(p22phox) causing about 25%, 5% and 5% of cases, respec-
tively. Defects in the fifth necessary component (rac2) give
rise to a spectrum of neutrophil dysfunction, including a
CGD-like syndrome [8,317] although oxidase activity can be
normal in these cells, depending upon the stimulus used [7].
In most cases, the genetic mutation results in the com-
plete loss of the protein for which it codes. Rarely the
mutation affects a regulatory, nonstructural, part of the
protein, and in these cases, the protein is expressed but
does not function. Under these circumstances, the mutation
can be very instructive as to the normal role of that part of
the molecule in the active oxidase complex. Analysis of
these mutations has provided much of the specific evidence
of the domains responsible for protein/protein interactions
of the subunits and the binding of the redox centers to
flavocytochrome b558.
A small subgroup of CGD patients have what is known
as ‘‘variant’’ CGD [194]. In these cases there is partial loss
of a protein or its function and often as much as 10%
[33,157,247], and up to 30% (Malech, H., personal com-
munication), of normal oxidase activity can be measured.
No instances of CGD have been identified where a lesion
of p40phox is causal. This could mean that it only plays a
relatively unimportant regulatory role, or that mutations
result in a lethal phenotype.6. Cell biology of oxidase components
6.1. Cell distribution
The NADPH oxidase is primarily found in the profes-
sional phagocytic cells. These include neutrophils, mono-
cytes, macrophages (including various members of the
macrophage lineage such as Kupffer cells in the liver,
alveolar macrophages, microglia in the CNS) and eosino-
phils. It is not present in the immature promyelocytic HL-60
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following induction [245].
There have been reports of this oxidase in other cells.
These include fibroblasts [203] although this activity seems
to be produced by another superoxide generating system
[204] possibly a NOX isoform. It was also suggested that it
might play an oxygen-sensing role in carotid body cells in
which it was thought to have been detected [4]. Oxygen
sensing is normal in mice lacking gp91phox [11] and another
sensing system seems to be operative in most cells [200].
6.2. Subcellular distribution
The initial description was that the flavocytochrome was
distributed between the plasma membrane and specific
granules in neutrophils [265,267,271] from which it was
incorporated into the wall of the phagocytic vacuole [267].
There has been some disagreement with this initial
assignment of location with the suggestion that almost all
the flavocytochrome b resided in the membrane of the
specific granules [24] and that activation involved the fusion
of these granules with the phagocytic vacuole. This does not
explain the subcellular distribution of the flavocytochrome
in monocytes, macrophages, eosinophils [261] or HL-60
cells [245], none of which contain specific granules.
It has also been proposed that the small amount of
flavocytochrome b associated with the membranes is not
found in the plasma membrane but in a distinct organelle
called the ‘‘secretory vesicle’’, which is suggested to act as aFig. 7. Schematic representation of the components of the active NADPH oxidase
from the cytosol to the membrane where they interact with the flavocytochrome
bound state in association with GDI. The interaction of these factors might indu
substrate NADPH access to its binding site.storage system for plasma membrane associated molecules
[35,275]. However, these ‘‘organelles’’ contain relatively
large amounts of human serum albumin which can only
have arrived there by endocytosis of the plasma into
invaginated plasma membrane. There would not seem to
be an obvious need to consider these secretory vesicles as
unique organelles, and that the association of the flavocy-
tochrome b558 with the plasma membrane should suffice.7. Activation of the NADPH oxidase
7.1. Cytoskeletal interactions, conformational changes and
phosphorylation
After a particle is phagocytosed, the oxidase is activated
after the vacuole has closed [270], and only in that region of
the plasma membrane that makes up the wall of the vacuole
[29] (Fig. 7). Targeting of an active oxidase to this part of
the membrane appears to be dependent upon the accumula-
tion of phosphatidylinositol phosphates at this site. The
characteristic lag of about 20–30 s between the activating
stimulus and oxidase activity [259] is probably accounted
for by PIP metabolism and translocation of the cytosolic
factors, although the cell-free system (which is independent
of PI metabolism) also exhibits a lag (Section 8.1).
The vacuolar membrane is the site of activity of PI3
kinases and phosphatases that act on phosphoinositol to
generate a variety of phosphoinositol phosphates (PIPs). Cytosolic factors, p47phox and p67phox are phosphorylated and translocate
b and with p21rac which is normally maintained in the cytosol in its GDP
ce electron transport by inducing a conformational change, providing the
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homologous stretches of 120–130 amino acids that form a
structure called the phox homology or PX domain [239] (Fig.
6) that binds to these PIPs and directs these proteins to this
activated membrane [161,328] (reviewed by Wientjes and
Segal [316]). There are slight differences in the PIP binding
pocket of p40phox and p47phox resulting in different specific-
ities of the associations [161]. p47phox [144] has a greater
affinity for PI(3,4)P2 than PI(3)P whereas the binding pocket
of p40phox [28] is too cramped for PI(3,4)P2 but binds PI(3)P
tightly. p40phoxmight be responsible for transporting p67phox,
which does not contain a PX domain, to the membrane.
The cytoskeleton also plays a role in the dynamics of the
movement of cytosolic components. Initially a dense mesh-
work of polymerised cytoskeletal proteins lines the mem-
brane at the base of the phagocytic vacuole and protrudes all
around it to produce the pseudopodia around the phagocytic
cup which then unite around the particle to close the
vacuole. The vacuole then migrates to the interior of the
cell, rupturing through the polymerised cytoskeleton as it
does so. However, it still remains surrounded by a network
of cytoskeletal proteins such as coronin, paxillin and
vimentin [125,241]. The influence of the different states
of the cytoskeletal proteins on the access of the substrate to
the flavocytochrome and of the cytosolic phox proteins and
rac to the membrane is unknown. p47phox and p67phox do not
exist in simple solution in the cytosol, but are associated
with the cytoskeleton, in particular with moesin, coronin
and actin [125,216,291,315,320].
Phosphorylation of gp91phox [114], p22phox [114,243],
p67phox [93,103] and p40phox [27,285] is seen in association
with activation of the oxidase and may only involve a small
fraction of these proteins. However, the most heavily phos-
phorylated of all the components is p47phox, which is
phosphorylated at multiple serine residues [143]. The most
important sites appear to be S379, S303/304 and S359/S370
[98,158] (Fig. 6) and may function in an hierarchical fashion,
some being phosphorylated in the cytosol and being required
for translocation, while others being phosphorylated at the
membrane and being required for activation itself [158] and
likely causing a conformational change [76,228,229]. The
kinases involved have not been clearly identified although
many have been implicated [145,176,184,220,227]. Phos-
phorylation of specific p47phox residues may also be in-
volved in deactivation of the oxidase [227].
Activation of electron transport depends upon a change in
the conformation of the flavocytochrome, possibly providing
NADPH access to the active site. Alternatively, electron
transfer may be facilitated between the flavin and haem of
flavocytochrome b558 [47,83]. The former mechanism might
be accomplished by displacing the small helix that is pre-
dicted in the molecular model to occupy this binding site in
the inactive state [293]. This conformational change appears
to require contact between the cytosolic proteins and the
flavocytochrome b558, and to do that, the phox proteins have
to move from the cytosol to the vacuolar membrane. Thismovement is accomplished by specific changes in the mem-
brane of the vacuole and in the proteins themselves.
7.2. Intermolecular associations of the components of the
NADPH oxidase
Our knowledge regarding the assembly of the oxidase is
indirect in the absence of structural evidence of the inter-
molecular interactions. We know that the cytosolic phox
proteins transiently associate with phagosomes [6] but that
this association is unstable when the flavocytochrome is not
present [141,143] (Fig. 7).
p67phox attaches directly to flavocytochrome b558, and in
combination with rac in the GTP bound form, is sufficient to
induce electron transport [47,70,106,178] although in the
absence of p47phox, micromolar rather than nanomolar con-
centrations of p67phox are required [47,178]. Rac2 trans-
locates to the membrane [3] independently of the cytosolic
phox proteins [140], and also binds to the flavocytochrome
b558. Chimeras of rac and p67
phox also elicit superoxide
production [118,207]. In the absence of p47phox, much greater
concentrations of p67phox are required for activity and the
complex with the flavocytochrome b558 is less stable. p47
phox
appears to be an adaptor molecule that forms a bridge
between p22phox and p67phox, as well as binding to cytoplas-
mic regions of gp91phox [78,178], thereby stabilising the
attachment of p67phox to flavocytochrome b558. There is also
evidence that p47phox does functionally affect flavocyto-
chrome b558 directly [46,47,61]. p47
phox has two SH3
domains, the ligand binding domains of which face each
other to form a groove in which its C-terminal polybasic
region fits [124]. It has been suggested that upon activation
this polybasic region is phosphorylated, inducing a release
from its autoinhibitory role and making the groove accessible
to bind the proline-rich tail in the C-terminal portion of
p22phox [124,226,229,280,289]. Arachidonic acid generated
through the activity of phospholipase-A2 might be important
for activation of the oxidase in the intact cell [68]. There is
also good evidence that p47phox directly interacts with cyto-
plasmic loops of gp91phox [79,251].
The mechanism by which rac promotes activation by
p67phox, to which it binds [84], remains to be clarified. It is
not known what causes the separation of rac from its
complex with GDI in the cytosol. It translocates to the
membrane independently from p67phox and p47phox [82,
118,119,140] and its GDP is probably exchanged for GTP
on the membrane through the action of P-Rex1, a 185-kDa
guanine-nucleotide exchange factor (GEF) [311], that is
activated by PtdIns(3,4,5)P3 and the hg subunits of hetero-
trimeric G proteins.
The requirement for p40phox in controlling NADPH
oxidase activity is rather obscure. p40phox becomes phos-
phorylated during neutrophil activation and translocates to
the plasma membrane in a similar manner to p47phox. Unlike
the bulk of p47phox, in resting neutrophils p40phox and
p67phox are largely associated with the cytoskeleton. Work
Fig. 8. Equilibrium model for NADPH oxidase activation. This model is a
simplified version of the kinetic model developed in reference [47]. In this
model, the anionic amphiphile causes a change in conformation in p47phox
that allows it to associate with flavocytochrome b558. This association
allows the high affinity binding of p67phox and rac resulting in an
intermediate activation state where electron transfer can occur from
NADPH to FAD. The formation of this intermediate state is relatively
rapid. A subsequent slow step, possibly involving a conformational change
in flavocytochrome b558, results in the fully active oxidase. The occupancy
of each activation state may be influenced by additional factors, such as
Mg2 + [49].
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[254,303] and positive [45,97,300] regulatory roles for this
protein. The finding that it is responsible for translocating
p47phox and p67phox to the vacuolar membrane [183] makes
the latter more likely and its principal role may be targeting
to PIP-rich regions (Section 7.1).
Although p40phox is not required for activity of the
cell-free oxidase system, it can modulate this activity.
Using recombinant cytosolic proteins, it has been shown
that p40phox increases the affinity of p47phox for flavocy-
tochrome b558 [45]. This finding sprang from the obser-
vation that ‘‘recombinant cytosol’’ (rp47phox, rp67phox,
rprac2) could only activate oxidase activity weakly when
added to crude neutrophil membranes, yet was fully
competent in activating purified flavocytochrome b558.
This deficiency could be partially overcome by the
addition of rp40phox (or a sub-stimulatory ‘‘spike’’ of
natural cytosol) to the activation mixture. These experi-
ments also suggest that p47phox is the limiting component
in neutrophil cytosol [50]. In the absence of p47phox,
p40phox could elicit a small amount of oxidase activity
(f 5%), possibly by increasing the affinity of p67phox
and/or Rac for flavocytochrome b558 [45]. It was pro-
posed p40phox could increase the affinity of p47phox for
flavocytochrome b558 by promoting the conformational
change in p47phox that occurs during activation; co-
operatively increase the binding of p47phox by binding
to both p47phox and flavocytochrome b558; or bind to
p67phox and/or rac2 in such a way as to increase their
affinity for cytochrome-associated p47phox.8. Regulation of electron flow
8.1. Mechanisms and kinetics
In both whole cells and cell-free NADPH oxidase
activation systems, there is a characteristic lag before
oxidase activity appears after the addition of stimulus (to
whole cells) or amphiphile (in cell-free systems). By
exploiting this phenomenon and the steady-state levels
of reduction of haem and flavin, several laboratories have
obtained evidence that the cytosolic factors have individ-
ual roles in regulating electron flow within the oxidase
[46,47,61,83,179,218]. In principal, this may be achieved
by controlling the oxidase at several points: (1) binding
of NADPH to the enzyme; (2) electron (hydride) transfer
from NADPH to FAD; (3) electron transfer from FAD to
the inner haem; (4) electron transfer between the haems;
and (5) electron transfer to oxygen. In fact, it appears
there is control of electron flow at two distinct points:
between NADPH and enzyme FAD, and between enzyme
FAD and haem [46,61,83]. This results in a situation in
which the oxidase exists in at least three kinetic states:
inactive, intermediate and fully active. In the intermediate
state, electron transfer can occur from NADPH to theflavin center of flavocytochrome b558, but not to the
haem or oxygen (Fig. 8). Electron flow to the flavin can
be measured by a dye reductase assay, since the dye
iodonitrotetrazolium iodide accepts electrons directly from
reduced, enzyme-bound FAD [47,50,61]. Thus, the inter-
mediate state of the oxidase can be analyzed in cell-free
assays using highly purified or recombinant proteins.
Measurements of the kinetics of activation of oxidase
activity using INT or O2
 formation as outputs showed
that there is significant INT reductase activity before the
appearance of O2
, depending on the incubation condi-
tions. Similarly, in the presence of INT, the onset of
NADPH oxidation is much shorter than in its absence.
Thus, the formation of the intermediate state is relatively
rapid compared to the conversion of the intermediate
state to the fully active oxidase [47]. In the fully active
enzyme, steady-state measurements of the reduction level
of flavin and haem indicate the rate-limiting step
becomes electron transfer from NADPH to FAD, and
not the binding of NADPH or the later electron transfer
steps. It is this first step that appears to be principally
regulated by p67phox [179,218]. Bokoch and Diebold [83]
have proposed that Rac and p67phox have independent
roles in regulating this electron transfer step, but must
interact with each other in order to activate the electron
transfer steps subsequent to FAD reduction. Differential
[105] regulation of the initial electron transfer step
(NADPH! FAD) from subsequent electron transfer
step(s) by the individual cytosolic factors (or amphiphile)
may form the mechanistic basis for the intermediate state
of oxidase activation.
There is also evidence that the anionic amphiphile
may play a direct role in regulating electron transfer (in
addition to its effect in causing a conformational change
in p47phox [50,280,289]). Two possible mechanisms can
be envisaged. First, the amphiphile may assist the cyto-
solic factors in causing a change in the conformation in
Fig. 9. Proposed toxic products of NADPH oxidase in neutrophils. The
oxidase generates superoxide which dismutates to form hydrogen peroxide.
The peroxide and superoxide can react to produce hydroxyl radicals in the
presence of metal ions. Hydrogen peroxide can also serve as substrate for
myeloperoxidase mediated oxidation of halides. Reactive oxygen species
and hypohalous acids could produce damaging interactions with cellular
constituents.
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induce a change in the axial co-ordination of one of the
haems, possibly enabling it to bind O2 [90,199] (Section
3.1.3).
Importantly, and surprisingly, the activation process is
thought to be catalytic and dynamic in nature, rather than
through the formation of a fixed stoichiometric complex
[48]. It has been generally assumed that the activation of
NADPH oxidase involves the formation of a stable
complex between flavocytochrome b558 and the cytosolic
factors in a stoichiometric complex. Further, it is assumed
that this association converts flavocytochrome b558 (con-
taining all the catalytic machinery) from an inactive to an
active state and dissociation converts the flavocytochrome
b558 back to the resting form. However, simple titration
experiments strongly suggest that in the cell-free system
at low ratios of p67phox (and to a lesser extent Rac2),
these proteins are capable of activating flavocytochrome
b558 in a catalytic fashion, rather than through the
formation of a stoichiometric complex. In these experi-
ments, it was found that one molecule of p67phox was
competent to activate a minimum of five flavocytochrome
b558 molecules, and similar (but less pronounced) effects
were seen for Rac2. It was proposed that after undergo-
ing a conformational change induced by p67phox and
Rac2, flavocytochrome b558 remains in the activated state
for a significant period after the cytosolic factors have
dissociated.
This suggests that a dynamic equilibrium exists be-
tween (at least) the three states of the oxidase (inactive,
intermediate and active, described above and in Fig. 8).
Under normal conditions the inactive conformation of
flavocytochrome b558 is exclusively favored over other
conformations. Interactions with p67phox and Rac2 drive
the favored conformation toward the intermediate and
activated states; the conversion process(es) being relative-
ly slow [47].
Support for this concept is provided by the observation
that in a specific detergent and lipid environment, purified
guinea pig flavocytochrome b558 displays NADPH-depen-
dent, O2
-generating activity independent of anionic amphi-
phile or cytosolic factors [180,181]. This [181] suggests the
role of lipid and cytosolic subunits is to perturb the
equilibrium that normally favors an inactive flavocyto-
chrome b558 to favor the active form. Perhaps due to
methodological differences, the preparations of Koshkin
and Pick [180,181] are in an environment that is more
favorable to the active conformation of flavocytochrome
b558 even in the absence of cytosolic phox proteins. Con-
sequently, they observe significant oxidase activity in the
absence of p47phox, p67phox, Rac and amphiphile (although
the presence of these molecules enhances activity in their
experiments).
The conformational change responsible for these changes
in activity may involve displacement of residues that nor-
mally block the NADPH binding site [293], changes in therelative orientation of the redox centers to facilitate electron
transfer, a change in spin state of the haem(s) [87,90,199] or
a combination of these factors.
8.2. Oxidase inhibitors
Despite an intensive search, the identification of a truly
specific inhibitor of NADPH oxidase has proved elusive,
although more than 120 had been described by 1990 [44]
and more than 350 have been described in the current
literature (Cross, unpublished). This susceptibility to inhi-
bition is perhaps due to the complex nature of the oxidase
and its regulatory pathways. The most widely used inhibitor,
diphenylene iodonium [52], has like most inhibitors ‘‘lost
specificity over time’’ and is now known to inhibit many
flavoproteins, including xanthine oxidase (a source of O2
)
and nitric oxide synthase. Two inhibitors that may stand the
test of time are apocynin [283] and a gp91phox-tat fusion
peptide [244].9. Products of the oxidase and indications as to their
antimicrobial role
9.1. Reactive oxygen species
Oxygen radicals and their reaction products, collec-
tively referred to as reactive oxygen species (ROS), are
produced as a consequence of NADPH oxidase activity
(Fig. 9). Since ROS can react with organic molecules,
and because the oxidase is required to kill a number of
important microbial pathogens, an enormous body of
literature has developed that has causally linked the
ROS directly to the death of the microbe. Extrapolations
from these studies have implicated ROS in a wide range
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have been proposed as panaceas for their prevention
and treatment. There were many good reasons for be-
lieving the theories relating to the direct toxicity of
oxygen radicals and their metabolites. They sound reac-
tive, and therefore toxic! Ionizing radiation, which gen-
erates free radicals, is clearly highly toxic to cells,
although this is predominantly through damage to
DNA. As will be described below, many of these issues
need to be readdressed.
9.1.1. O2

Although the superoxide anion radical, O2
, had been
recognised in chemical systems for many years, the proof of
its existence in biology followed the discovery of the
enzymatic function of superoxide dismutase by McCord
and Fridovich [201]. It was not long before it was shown
that neutrophils produce large amounts of O2
 [14] which
then dismutate to produce the previously observed H2O2
[153].
Despite concerns relating to its toxicity [99], it was
claimed that O2





 and H2O2 can combine to generate the very reactive
hydroxyl radical (HO
S
) in the Haber–Weiss reaction. This
requires a metal such as iron in the Fenton reaction,
Fe2 + +H2O2! Fe3 + +HO+HOS. HOS has been mea-
sured in a broken cell preparation [7] and has been impli-
cated as a microbicidal agent [249]. These radicals are
probably not found in intact cells [40] because lactoferrin,
which is unsaturated in neutrophil granules, inhibits the
generation of HO
S
[30] and other free-radical reactions
[127] by binding free copper and iron.
9.1.3. H2O2Fmyeloperoxidase
H2O2, which is used as a topical antiseptic [208], is
produced by neutrophils and has been thought to be
capable of killing microbes within them [39,195]. In
combination with myeloperoxidase (MPO), a very abun-
dant protein in neutrophils (which gives pus its charac-
teristic green colour), it was thought that this enzyme
catalyses the H2O2-dependent oxidation of halides that
can react with and kill microbes. Experiments with the
myeloperoxidase–H2O2–halide system demonstrated that
this enzyme can kill bacteria in the test tube
[130,131,167,168,170], and myeloperoxidase mediated
halogenation has been the accepted basis of microbial
killing for several decades.
Supportive evidence was provided by the finding that
catalase negative organisms rarely infect patients with CGD
[112]. The explanation was that these bacteria generated
enough H2O2 to catalyse their own MPO-mediated haloge-
nation within the vacuole of the neutrophil [147,238]. In
vitro mutagenesis was used to generate strains of Staphylo-coccus aureus containing varying levels of catalase. Their
virulence in mice was found to be inversely proportional to
their catalase content [198]. Recently, however, doubts have
been cast upon this theory. Catalase-deficient A. nidulans
[36] and S. aureus [205] were shown to be as virulent as the
catalase-positive varieties in a mouse model of CGD.
9.1.4. Ozone
More recently, it has been found that antibodies can
catalyse the formation of ozone [312], and this has also been
suggested as a possible mechanism by which bacteria might
be killed and inflammation induced.
Experiments with 15O2 showed [258] that almost all the
O2 consumed goes to form water, and little if any is
incorporated into the organic matter of the cell or microbe.
9.2. A new approach to the relationship between NADPH
oxidase and microbial killing
Although the proposal that ROS would be toxic to living
cells is intuitively attractive, it was never adequately tested
under the conditions pertaining in the phagocytic vacuole.
The opportunity was provided by the development of gene
targeting which allowed a mouse model to be constructed
which was lacking the major neutrophil proteases, elastase
and cathepsin G [241,297]. The essential nature of these
proteases in the killing process was demonstrated by the fact
that this mouse was very susceptible to infection by the
same bacteria and fungi that infect CGD patients, and that
its neutrophils failed to kill these organisms in vitro. The
different organisms showed different susceptibilities to the
different proteases. Most importantly, these cells failed to
kill the microbes despite an entirely normal respiratory burst
and microbial induced iodination. This meant that two
separate components of neutrophil biology are required, a
normal respiratory burst and a normal complement of
granule proteases, and the challenge was to understand the
interaction between the two.
The first step to this understanding was to know the
conditions under which the products of the oxidase and the
granule proteins interact within the vacuole. From knowl-
edge of the O2
 generated in response to the uptake of a
bacterium and the volume of the vacuole as measured on
electron micrographs, the amount of O2
 pumped into the
vacuoles can be calculated. It turns out to be enormous—in
the region of 4 mol/l. This gargantuan concentration of O2

generation is required for effective killing. Some rare
patients with CGD have been described in whom the
molecular defect is incomplete and some oxidase activity
can be detected [33,142,247]. These ‘‘variant’’ patients
often demonstrate 10% (and exceptionally up to 30%,
Malech, H., personal communication) of normal levels of
activity. Thus, these patients are producing at least 400 mM
O2
 but can be as severely affected clinically as those with
complete defects. These levels of substrate should be more
than adequate for enzymic reactions, and yet they are not
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cal alteration by the oxidase rather than the production of an
enzyme substrate. In this regard, it should be noted that a
high concentration of protein, approximately 500 mg/ml,
and associated sulphated proteoglycans [175] are released
from the granules into the vacuole.
An important additional consideration is that of the pH.
Initially the vacuolar pH was thought to become acidic by
analogy with that found after several hours in secondary
lysosomes of macrophages [221]. In fact, the oxidase
initially causes the pH in the vacuole of neutrophils to rise
to about 7.8–8, after which it slowly falls [263] for the
reasons described in the following sections.
9.3. Compensation of the charge across the vacuolar
membrane
The oxidase is electrogenic, transferring electrons, unac-
companied by protons, across the vacuolar membrane
[72,135,162,256]. The vacuolar volume is about 0.2 A3 with
a membrane surface area of about 1.65 A2. O2 of 0.8–2.0
fmol is produced in each vacuole and thus about 5–
10 108 electrons pass across each square micron of
membrane. The charge on one electron is 1.6 10 19 C,
so 3–7 108 charges in 1 A2 would produce 4.6 10 3 to
1.2 10 2 C/cm2, which, taking the capacitance of the
membrane at about 1 AF/cm2 [234], would depolarize the
membrane potential by 4600–11,700 V! Therefore, the
charge must be compensated, if electron transport is not to
cease almost immediately. It was demonstrated recently that
depolarization of the membrane to + 190 mV shuts down
NADPH oxidase activity completely [75]. This finding
confirms the expectation that electron extrusion will be
opposed by voltage, and that charge compensation is abso-
lutely required for continuous NADPH oxidase function.
9.3.1. Charge compensation by protons
One of the problems of studying charge compensation
across the phagocytic vacuole is inaccessibility. Thus, many
studies are conducted in which the cell/s are stimulated with
soluble activators of the oxidase, such as PMA, under which
circumstances a number of different but related processes
are taking place at the plasma membrane. In addition to
electron transport [256], there is movement of the compen-
sating ions, and also the movement of protons and other ions
to correct for the fall in pH produced by the oxidase, and
these two are not necessarily the same.
In addition to the protons remaining in the cytoplasm as a
result of charge separation when the electrons are trans-
ported from NADPH across the wall of the phagocytic
vacuole, additional protons are produced in the cytosol by
the hexose monophosphate shunt, which generates NADPH
[26], as well as during the production of energy by glycol-
ysis. This proton generation by an active oxidase, estimated
to be about 150 mmol/l [213], causes an initial slight fall in
cytosolic pH which rapidly returns to normal.Three mechanisms appear to be associated with the
extrusion of these H+s which are extruded in roughly
equimolar quantities with the O2
 generated [290,302].
The predominant one is a Na+/H+ antiport [122,282], and
its inhibition by the removal of extracellular Na+ or block-
age with amiloride causes acidification of the cytosol upon
stimulation of the cells. In addition, both Zn2 + and Cd2 +
blockable proton channels [136,212] and vacuolar (V)-type
H+ pumps, inhibited by bafilomycins [213], are also present.
It is generally agreed that the charge induced by electron
translocation (Ie) through the NADPH oxidase is compen-
sated by proton efflux [75,135,137]. The identity of this
channel is currently very contentious. On the one hand, there
is a school of thought that proposes that the protons pass
through voltage-gated proton channels that are distinct from
any NADPH oxidase component [73,74,210] whereas the
opposing view is that they pass through the flavocytochrome
b of the oxidase, gp91phox, itself [138,199,214,299].
One of the hallmarks of the assumption that Ie is largely
compensated by proton fluxes is that both Zn2 + and Cd2 +,
known proton channel blockers [74,136,295], were also
thought to inhibit O2
 production [75,137]. The discrepancy
between the low AM concentrations of these cations that
block proton channels and the mM concentrations needed to
inhibit cytochrome c reduction, was recently explained by
the voltage dependence of Ie whereby Zn
2 + and Cd2 + shift
the threshold voltage for activating voltage-gated proton
channels into the steeply voltage-dependent region of Ie,
thereby attenuating O2
 production [75].
However, Zn2 + and Cd2 + do not in fact inhibit the
NADPH oxidase, as they have no effect on oxygen con-
sumption but interfere with the superoxide detection system
by accelerating the dismutation of superoxide to hydrogen
peroxide, thereby bypassing the reduction of cytochrome c.
In a system in which xanthine–xanthine oxidase generated
O2
, 3 mM concentrations of these elements induced the
dismutation of O2
 to H2O2 at a rate indistinguishable from
that catalysed by superoxide dismutase (1 Ag/ml). Zn2 +, at
concentrations three orders of magnitude greater than those
causing almost complete blockage to proton channels, was
also without effect on the currents measured in electrophys-
iological studies performed on neutrophils and on eosino-
phils, or on PMA induced 86Rb efflux from these cells [5].
9.3.2. Charge compensation by K+
The changes in the vacuolar pH (Fig. 10) hold the key to
understanding the nature of the compensating ions [80,156].
This pH is elevated from that of the extracellular medium to
7.8–8.0 [263] despite the release into the vacuole of 500
mg/ml granule protein contents [241] that are maintained at
pH 5.0 in the granule by a proton pump [286]. These
granule contents are strong buffers and it required about
400 Amol of KOH per gram of granule protein to elevate the
pH from 5.0 to 8.0 [241]. Because the vacuole becomes
alkalinised despite the entry of these acidic granule contents,
the compensating charge cannot be solely in the form of H+
Fig. 10. Schematic representation of ion fluxes and influence on pH of phagocytic vacuole. The interior of the cytoplasmic granules is maintained at a pH of
about 5.0 by V-ATPases [123]. The degranulation of these contents into the vacuole causes it to become acidic. The superoxide and its dismutation product,
peroxide, become protonated, consuming protons in the vacuole and driving the pH up. The passage of electrons across the vacuolar membrane to produce O2

generates a charge across the membrane that must be compensated by the passage of other ions for electron transport to continue. The nature of the ions
compensating this charge has a profound effect on the pH in the vacuole. The movement of protons prevents the consumption of those within the vacuole and
the pH is not elevated whereas other ions such as Cl from, or K+ to, the vacuole cause it to rise.
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neutral (see below).
The only ion other than H+ that is present in the
cytoplasm at high enough concentrations to compensate
the charge by passing into the vacuole is K+. It accumulates
in the vacuole at concentrations of up to about 600 mM as a
consequence of oxidase activity [241]. Transport of K+ ions
is markedly diminished when the pH rises above 8.0. Thus,
charge compensation by K+ provides an important self-
regulating mechanism for elevating the vacuolar pH to
between 7.8 and 8.
K+ flux only accounts for about 6% of the compensating
charge [241] and since the proton channel does not appear to
compensate all the rest of the charge because its inhibition
does not block the NADPH oxidase, some other major ion
flux must be involved.
9.3.2.1. The K+ enters the phagocytic vacuole through the
large conductance Ca2+-activated K+ channel. It is
known that neutrophils have a high intrinsic permeability
to K+ ions and contain a number of different types of K+
conductances. These include inwardly rectifying K+ chan-
nels [197], voltage-gated K+ channels and Ca2 +-activated
K+ channel [182] and ATP-sensitive K+ [281] channels. K+
enters the phagocytic vacuole through the large conductance
Ca2 +-activated K+ channel [5]. Iberiotoxin (IBTX) and
paxilline (PAX), both highly selective and potent inhibitors
of the BKCa channel [113,253,310], prevented the alkalin-
isation of the vacuole. The IC50 values for this effect were in
the region of 10 nM for IBTX and PAX, consistent withtheir IC50 for channel block [38,154]. In addition, the BKCa
channel opener, NS1619 [186], significantly augmented the
rise in pH to supra-normal levels. A variety of blockers and
openers of other K+ channels were without effect.
86Rb+ release from activated neutrophils after stimulation
with PMA was also induced by the BKCa channel opener
NS1619, and even further enhanced by the combination of
this opener and PMA. PMA-induced efflux and that caused
by NS1619 were both completely abrogated by IBTX and
PAX.
BKCa channels are classically opened by the combination
of membrane depolarisation and elevated [Ca2 +]c [159]. The
same was found to hold true for this channel in neutrophils
and eosinophils. Neither depolarising the membrane nor
elevating the cytosolic [Ca2 +] was sufficient to fully open
the K+ channel, whereas the combination of these caused as
much channel opening as did stimulation with PMA.
Although PMA stimulation is well known to depolarise
the neutrophil plasma membrane [155], it is generally
thought not to elevate [Ca2 +]c. One mechanism by which
this might occur could be through a drop in pH just beneath
the plasma membrane as a consequence of charge separation
induced by the oxidase. Corresponding elevations in
[Ca2 +]c and falls in pH were seen just beneath the plasma
membrane in activated cells [5].
9.3.2.2. The movement of K+ into the vacuole activates
elastase and cathepsin G. The contents of the cytoplasmic
azurophil granules are not freely in solution. They are
almost exclusively highly cationic proteins that are strongly
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heparin and chondroitin sulfate [175], in which state they
are inactive. They are activated in the vacuole both by the
elevation in pH described above, and by the hypertonic K+
that breaks the charged interaction between the enzymes and
the matrix, releasing them in a soluble form [241]. For these
hypertonic conditions to develop, water must be prevented
from entering the vacuole in response to the osmotic
attraction of the salts. This is achieved by encasing the
vacuole in a meshwork of cytoskeletal proteins, including
paxillin and vinculin.
The importance of the accumulation of K+ in the
vacuole was shown when this was abrogated either with
the K+ ionophore valinomycin [241] or by blocking the
BKCa channel with the specific inhibitors iberiotoxin or
paxillin [5]. In both cases, microbial killing and digestion
was almost completely prevented. The fact that the
microbes were not killed despite the generation of normal
quantities of ROS and normal levels of iodination proved
that these were not directly involved in the microbicidal
process, whereas inhibition of killing by removal of the
proteases cathepsin G and elastase proved that these
enzymes were.
9.4. Myeloperoxidase
Myeloperoxidase (MPO) is a di-haem protein comprised
of two identical heterodimers. Each heterodimer is formed
from the post-translational modification of a single poly-
peptide precursor. The two symmetric halves are linked by
disulfide linkage between the two heavy chains. The cova-
lently bound haem has a unique structure and exhibits
unusual spectral properties that are responsible for its green
colour [100]. MPO constitutes about 5% of the total
neutrophil protein and is present in the cytoplasmic granules
at very high concentrations. It makes up about 25% of the
granule protein to achieve concentrations of about 100 mg/
ml (1 mM) in the vacuole.
Experiments with the myeloperoxidase–H2O2–halide
system demonstrated that this enzyme can kill bacteria in
the test tube [130,131,167,168,170]. However, these
experiments were conducted under unphysiological con-
ditions, with relatively low concentrations of MPO (50 Ag/
ml), at low pH (5.0) and, most important of all, in the
absence of the high levels of proteins found in the vacuole.
When bacteria were exposed to 100 mM H2O2 or 1 mM
HOCl in the presence of 25 mg/ml granule proteins
(technically much more manageable than the experimen-
tally determined 500 mg/ml), killing was almost abolished
[242]. Neutrophils clearly iodinate and chlorinate proteins
when bacteria are phagocytosed, and this halogenation is
dependent upon an active NADPH oxidase and myeloper-
oxidase [171]. However, it is not the bacterial protein that
is being iodinated [262] and chlorinated [37] but the
proteins of the enveloping neutrophil, particularly those
from the cytoplasmic granules. This would be a highlyinefficient system if its primary purpose was to halogenate
bacterial proteins.
A few patients were discovered whose neutrophils lacked
MPO, who were also thought to be immunodeficient [187]
and recently an MPO ‘‘knock-out’’ mouse was shown to be
susceptible to yeast but not bacterial infection [9]. However,
the advent of automated differential leukocyte counting
machines, where the identification of neutrophils was de-
pendent upon a peroxidase stain, revealed that about 1 in
2000 of the general population is MPO deficient without
any undue predisposition to infection [215], and the neu-
trophils of birds do not contain MPO [235].
One possible function of this enzyme is to protect the
digestive enzymes from oxidative denaturation by removing
H2O2 from the phagocytic vacuole, rather than the tradi-
tional antimicrobial function ascribed to it.
MPO has catalase activity [165] but this only functions
efficiently if the compound II that accumulates is reduced
back to the native enzyme. This can be achieved by the high
concentrations of O2
 in the vacuole with which MPO forms
an adduct to produce compound III [318].
It is also possible that MPO has a dual function, as a
catalase under the conditions pertaining in the vacuole, but
in a microbicidal capacity outside the cell where levels of
enzyme and substrate would be much lower, and the pH is
also generally low at sites of infection and inflammation.10. The NOX family
Recently, six human homologs of gp91phox have been
identified (Table 2).
10.1. Nomenclature of phox proteins
The phox family of proteins (p22phox, gp91phox, p47phox,
p67phox and p40phox) is named for phagocyte oxidase. Their
corresponding genes are CYBA and CYBB [for cytochrome
b subunits a (p22phox) and h (gp91phox)]; NCF1 (p47phox),
NCF2 (p67phox) and NCF4 (p40phox) (for Neutrophil Cyto-
solic Factor). NCF3 turned out to be rac2. The NOX
(NADPH OXidase) and DUOX (DUal OXidase) nomencla-
ture was agreed by interested parties at the Gordon Research
Conference on Phagocytes in June 2001. The NOXO1 and
NOXA1 (for NOX Organizer 1 and NOX Activator 1) terms
were adopted by researchers attending the Banbury Center
Conference on NADPH oxidases in November 2002. These
names have been approved by the HUGO Nomenclature
Committee.
10.2. General features
Evolutionary relationships revealed three main subgroup-
ings of the NOXs. The gp91phox subfamily consisting of
Nox1, gp91phox, Nox3 and Nox4 have molecular masses of
about 65 kDa. The Duox molecules comprise the second
Table 2
Members of the NOX/DUOX family of NAD(P)H oxidases and related cytosolic factors
Isoform (synonyms) Locus Tissue distribution Known splice forms Possible function
NOX1 (MOX1, NOH1) Xq22 Colon, smooth muscle 3 Mitogenic signaling/proton channel
NOX2 (gp91phox) Xp21.1 Myeloid 1 Host defense
NOX3 6q25.1–26 Fetal kidney 1 ?
NOX4 (Renox) 11 Kidney, vascular smooth
muscle, endothelium
1 Oxygen sensing/signaling
NOX5 15q22 Pancreas, placenta, ovary, testis 5 ?
DUOX1 (p138Tox) 15q21 Lung, thyroid, testis, prostate 2 Thyroxin synthesis/extracellular matrix
DUOX2 15q21 Colon, pancreas, testis 2 Extracellular matrix
NOXO1 ? Colon, testis ? p47phox analogue (for NOX1?)
NOXA1 ? Colon ? p67phox analogue (for NOX1?)
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group is contributed by two additional domains, a central
domain of two EF-hand calcium binding motifs and an N-
terminal peroxidase domain [185].
All the members of the NOX family have many structural
features in common with gp91phox. These include six
conserved transmembrane helices in the N-terminal half of
the protein, the third and fifth containing conserved pairs of
histidine residues 13 or 14 amino acids apart, equivalent to
the axial haem ligands of gp91phox (NOX2). A conserved
arginine residue is present at the equivalent position of
gp91phox R54 thought to form a hydrogen bond with a
haem propionate side-chain described above [60]. FAD- and
NAD(P)H-binding motifs are also conserved (Fig. 2). The
exonic structure of NOX1 and CYBB (the gp91phox gene) are
remarkably similar, testifying to their common origin,
although the intron sizes are very different, suggesting
relatively ancient gene duplication [166].
In general these proteins are expressed in epithelial cells,
and by analogy with gp91phox, would be expected to
transport electrons across membranes. Oxygen is probably
the recipient of these electrons, and it might be reduced to
form superoxide or H2O2. Because the levels of expression
of these systems are much lower than those of the NADPH
oxidase in phagocytes, and because natural lesions have not
been identified in these systems, gene targeting experiments
may be required before their functions and properties are
clearly resolved.
The transmembrane location of these molecules in epi-
thelial linings of the gut and kidneys, where large ionic
fluxes occur, suggests that they might be involved in these
fluxes, as has been shown for the neutrophil system.
10.3. Specific NOX systems
10.3.1. Nox1
The best characterized of the NOXs is the O2
-generating
NOX1 (originally named Mitogenic OXidase, MOX1) de-
scribed by Suh et al. [287]. Their work was prompted by the
fact that: (1) many tumor cells show increased production of
O2
 and other ROS; (2) cells exposed to growth factors
respond by increasing ROS production, and (3) cells ex-posed to ROS show increased proliferation (a well studied
example being vascular smooth muscle and endothelial
cells). Independently, Ba´nfi et al. [18] cloned the same gene
based on a sequence associated with H+ channels (gp91phox
is thought by some groups to conduct protons). Ba´nfi et al.
also reported the identification of two further gp91phox
homologs, and the Nox family has since grown to seven
distinct Nox genes, several of which have multiple splice
forms (Table 2).
NOX1 mRNA is expressed in colon, prostate, uterus and
vascular smooth muscle, but not in leukocytes (Table 2).
Lambeth’s group showed that platelet-derived growth factor
induced NOX1 expression in smooth muscle cells, and
expression of NOX1 in normal embryo fibroblasts (NIH
3T3 cells) increased O2
 production and cell growth.
Furthermore, cells overexpressing NOX1 take on a trans-
formed appearance, show anchorage-independent cell
growth and induce aggressive tumors in athymic mice.
This work showed that NOX1 might play a fundamental
role in the control of cell growth. Subsequently, they have
shown that NOX1 expression is a powerful trigger of
angiogenesis, promoting tumor growth [10]. NOX1 is
located at chromosome Xq22 and codes for a protein of
predicted length of 565 amino acids that shares 56%
identity with gp91phox. Recent work suggests it may be
regulated by its own versions of p47phox and p67phox,
NOXO1 and NOXA [114].
10.3.2. Other NOX family members
The second homolog described, NOX4 (originally Re-
nox, renal oxidase), is expressed in the renal cortex and
proximal convoluted tubule epithelial cells and was sug-
gested to be an oxygen sensor [115,279]. Expression of
NOX4 in fibroblasts resulted in increased O2
 production
and a senescent phenotype (in contrast to the transformed
phenotype induced by NOX1 expression). It was proposed
that NOX4 regulates the expression of erythropoeitin
through the generation of ROS that directly affect the
activity of transcription factors. Subsequently, NOX4 has
been found to be more widely expressed, and the discovery
of an unrelated flavin and haem containing oxygen sensor
(related to cytochrome b5 fused to cytochrome b5 reductase
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role of NOX4 as an oxygen sensor. Both NOX1 and NOX4
are expressed in the vasculature where there is an abun-
dance of recent literature supporting a central role for ROS
in both normal physiology and also pathology (reviewed in
[Refs. 121,224,313,323]). NAD(P)H oxidases are major
sources of O2
 in vascular cells and myocytes. In response
to growth factors and cytokines, they produce O2
 and
H2O2, which act as second messengers to regulate multiple
signaling pathways [319]. These vascular oxidases appear
to be essential to the physiology of vascular cells, regulat-
ing growth, cell migration and extracellular matrix compo-
sition. Dysfunction of ROS production has been linked to
hypertension, uncontrolled growth and inflammation, and
atherosclerosis. For example, excess ROS production has
been demonstrated in hypertension and aging [129], while
angiotensin-induced hypertrophy has been shown to be
ROS-dependent [327].
A substantial literature supports a role for p22phox (in
particular), p47phox and, to a lesser extent, p67phox, in the
regulation of NOX1 and NOX4 activities, but this is hard to
reconcile with the data from p22phox-, p47phox- or p67phox-
deficient CGD patients who appear to suffer no obvious
phenotypic abnormalities outside of their obvious suscepti-
bility to infection. The latter observation indicates that
p22phox, p47phox and p67phox are not absolute requirements
for NOX1 and NOX4 function and that other, as yet
unidentified, isoforms of these neutrophil factors probably
exist (such as NOXA1 and NOXO1, Section 4.2).
Presently, there is little information regarding the require-
ments of NOX3 and NOX5 for other regulatory subunits. In
the case of the ‘‘long’’ NOX family members, DUOX1 and
DUOX2, the presence of EF-hands presents the likelihood
of Ca2 + regulation, and both biochemical data [81,101,188],
disease studies [209] and thyroid expression [34,71,92]
support an essential role for one or both of these proteins
in thyroid hormone synthesis. Nevertheless, significant
expression outside thyroid tissue suggests these proteins
may perform other roles.
10.4. Functions of these proteins in other organisms
In C. elegans, the homologous DUOX has been shown to
play an important role in cross-linking of the extracellular
matrix. RNAi showed that reducing the activity of this
enzyme results in abnormal development and excessive
fragility of the cuticle [94]. Similarly, inhibition of DUOX
activity in drosophila causes fragile wings that become torn
and ragged (Lambeth, J.D., personal communication).
A related protein has recently been shown to be impor-
tant for root development in plants [104]. Plants such as
Arabidopsis contain multiple (>6) isoforms of these proteins
[164,298] and although some are known to be involved in
disease resistance [120] and iron uptake [246] (similar to
yeast), it is highly probable some serve signaling functions
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